• Patients who are:
  • Age 55-80
  • 30 pack-year smoking history
  • current smoking or quit in last 15 years
• Annual LDCT until quit for 15 years or new health condition significantly reducing life expectancy/treatment options
• Grade B, updated 2013

• Recommended for patients (Grade B):
  • Aged 50-59
  • ASCVD 10-year risk >= 10%
  • Not increased risk for bleeding
  • Life expectancy 10+ years
  • Willing to take for 10+ years
• Recommended for patients (Grade C):
  • Aged 60-69
  • ASCVD 10-year risk >= 10%
  • Not increased risk for bleeding
  • Life expectancy 10+ years
  • Willing to take for 10+ years
• Insufficient evidence for patients under 50 and over 70
• Updated 2016

• Asymptomatic pregnant women

• Adults 18+

• Women with:
  • a personal or family history:
    • breast
    • ovarian
    • tubal, or
    • peritoneal cancer
  • Women who have an ancestry associated with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations

should screen with appropriate brief familial risk assessment tool; if positive, receive genetic counseling and possibly tests (Grade B, August 2019)